Clinical trial
Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose long-term study to evaluate the maintenance of efficacy and safety of 1 to 3 mg/day of brexpiprazole as adjunctive treatment in patients with major depressive diso
Maintenance of efficacy during long-term treatment of brexpiprazole versus placebo as adjunctive treatment to antidepressants on depressive symptoms in patients with an insufficient response to antidepressant treatment
| Category | Value |
|---|---|
| Study start date | 2013-04-03 |